A Study of ERAS-601 in People With Chordoma

• Status: RECRUITING
• Trial end date: 2027-04-01

Summary

The researchers are doing this study is to find out whether ERAS-601 is a safe and effective treatment that causes few or mild side effects in people with advanced and progressing chordoma.

• Phase: PHASE1

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center